Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05215418 · ClinicalTrials.gov registry record · Phase 4
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
A Phase 4 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 4
- Development phase
- 565
- Enrollment target
NCT05215418 is a Phase 4 study that has completed, run by VIVUS. The registered enrollment target is 565 participants.
The verdict
NCT05215418, a Phase 4 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 565 participants
- Enrollment target
Study Summary
The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an active control (phentermine 30 mg).
Interventions
- DRUG Placebo
- DRUG Phentermine
- DRUG VI-0521
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2023-04-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05215418
The ClinicalTrials.gov registry entry for NCT05215418 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05215418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05215418 about?
NCT05215418 is a clinical study titled "A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects". The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an active control (phentermine 30 mg).
What is the current status of trial NCT05215418?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 565 participants. The study started on 2022-01-25. Estimated completion is 2023-04-17.
What interventions are being tested in trial NCT05215418?
The interventions under investigation include: Placebo (DRUG), Phentermine (DRUG), VI-0521 (DRUG).
Who is sponsoring clinical trial NCT05215418?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.